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Abstract 
MR elastography is a novel method for non-invasive fibrosis assessment, not yet 
sufficiently validated. In a recent study in 104 patients Park Gastroenterology 
2017;152:598-602), MRE was compared to transient elastography for the 
diagnosis of fibrosis is non-alcoholic fatty liver disease. The current viewpoint 
critically appraises this study. 
  
Non-alcoholic fatty liver disease (NAFLD) is a hugely prevalent condition 
affecting up to 30% of adults in the developed world. The diagnosis is associated 
with an increased risk of liver-related morbidity and mortality. The best 
determinant of major outcomes (liver-related events, need for liver transplant or 
death) is the presence of fibrosis on a liver biopsy. In a recent retrospective 
study of 619 NAFLD patients followed for a median of 12.6 years, Angulo and 
colleagues highlighted the independent association of any stage of liver fibrosis 
on biopsy (present in >50% of the study patients) and these outcomes. For 
instance, hazard ratios for factors associated with death or liver transplant 
included fibrosis stage 1 (HR, 1.88; 95% confidence interval [CI], 1.28–2.77), 
stage 2 (HR, 2.89; 95% CI, 1.93–4.33), stage 3 (HR, 3.76; 95% CI, 2.40–5.89), and 
stage 4 (HR, 10.9; 95% CI, 6.06–19.62) compared with stage 0. Conversely, the 
presence or severity of steatosis or steatohepatitis, a diagnostic feature of 
NAFLD and NASH, was not associated with outcomes.1 This valuable study 
underlined the importance of liver fibrosis detection in NAFLD patients to guide 
management and monitoring, but also the urgent need to identify robust non-
invasive fibrosis markers in order to avert the need for an invasive liver biopsy 
with the associated risks, cost, and impracticalities when considering such a 
significant patient population. 
Thankfully, a burgeoning market of non-invasive tests for liver fibrosis has 
developed over the past decade. These tests are either blood or imaging-based, 
with the former often utilized as cheaper screening tools with high negative 
predictive values allowing the reliable exclusion of advanced fibrosis (F3-F4); 
while the latter techniques are performed in specialist centres, and offer the 
advantage of a targeted assessment for liver fibrosis along with simultaneous 
detection of steatosis in NAFLD.2 Despite very good diagnostic performance for 
advanced fibrosis detection in NAFLD, both non-invasive techniques tend to lack 
diagnostic accuracy for delineating earlier fibrosis stages, an important factor 
when deciding on the need for aggressive therapy and follow up. Moreover, 
knowing that the presence of any fibrosis on biopsy has implications for disease 
outcomes means that a diagnostic test with high diagnostic accuracy across all 
fibrosis stages would be of significant value.  
In a recent prospective cross-sectional study by Park et al. from California, USA, 
two of the most studied imaging-based techniques for the non-invasive 
assessment of liver fibrosis, ultrasound transient elastography (TE) or 
Fibroscan®, and magnetic resonance elastography (MRE) were compared.3 
Elastography measures liver stiffness, a surrogate of liver fibrosis, by analysing 
the speed at which mechanical waves can propagate through the liver.  Both TE 
and MRE can also estimate liver steatosis simultaneously, using the controlled 
attenuation parameter (CAP) or MRI-based proton density fat fraction (MRI-
PDFF) methods, respectively. One short-coming of TE is high failure rates in 
obese patients, which has been reduced by the advent of an XL-probe. Indeed, 
another recent Japanese study by Imajo and colleagues also compared MRE with 
TE in NAFLD patients, but reported a 10% failure rate for TE in part due to a lack 
of the XL-probe.4 In the Park study both the standard ‘M’ and XL probes were 
available for use, potentially allowing a more meaningful assessment of the 
performance of MRE vs. TE in fibrosis detection in NAFLD. The authors also felt 
that the US-based cohort would yield more generalizable results to Western 
NAFLD populations than that described in the Imajo paper. The Park study 
involved 104 consecutive NAFLD patients who had undergone a liver biopsy, 
MRE and TE assessment. The patient cohort was 56.7% female, with a mean (+/-
SD) age of 50.8 (+/-14.6) years, BMI of 30.4 (+/-5.2) kg/m2 and diabetes 
prevalence of 27.9%. The XL probe was used in approximately 50% of cases, 
although a failure rate of 6.7% was reported. At first glance, the study results 
were impressive; MRE significantly outperformed TE in the detection of any 
stage of fibrosis (stage 1 and above), with an area under the receiver operating 
characteristic curve (AUROC) of 0.82 (95% confidence interval [CI], 0.74–0.91), 
for MRE compared with an AUROC of 0.67 (95% CI, 0.56-0.78) for TE 
(p=0.0116). MRI-PDFF detected any steatosis with an AUROC of 0.99 (95% CI, 
0.98-1.00), significantly higher than that of CAP (AUROC, 0.85; 95% CI, 0.75-
0.96), p=0.0091, and MRE was also significantly better at distinguishing grades 
of steatosis than CAP. 
Despite these positive findings, several issues limit the interpretation and 
application of the study results. Although MRE performed well in the primary 
study objectives, TE seemed to grossly underperform compared to other 
published studies.5 Indeed, the study cohort suffered from a clear ‘spectrum 
bias’, where stages of fibrosis were unevenly distributed amongst the group 
making meaningful comparisons difficult. The vast majority of patients had no or 
mild fibrosis (45.6% F0; 23.3% F1; 10.7% F2; 12.6% F3; 7.8% F4). This meant 
that that cut-offs used to determine the diagnostic accuracy for TE were atypical; 
for instance a value of 6.9kPa was the threshold for distinguishing F4 from F0-3 
stages, compared to a minimum of 11.7kPa in other, larger series.2 Unlike the 
Imajo study, no comparison was made with the efficacy of cheaper, more readily 
available, blood-based fibrosis scores such as the NAFLD fibrosis score (NFS) or 
the FIB-4 index. Indeed, the NFS performed as well as MRE in detecting any 
fibrosis, advanced fibrosis or cirrhosis in the larger group of 127 NAFLD patients 
from the Imajo study. Moreover, the MR facility used in the Park study was a 
3.0T MR scanner, whose use would be typically confined to research facilities 
and associated with a significant cost. Finally, although the detection of steatosis 
is useful to aid the diagnosis of NAFLD due to false negatives with standard 
ultrasound, the grading of steatosis does not appear to have implications for 
disease severity and long-term outcomes.1 Nevertheless, hepatic steatosis seems 
to closely reflect adipose insulin resistance specifically,6 and highly sensitive 
techniques such as MRI-PDFF may yet prove useful in determining treatment 
choice and response for this multi-system disease in the future.  
In conclusion, although MRE is a useful addition to the available non-invasive 
fibrosis tests, it requires further validation in larger cohorts of patients with 
more even distribution of fibrosis. Ultimately, what is required is a non-invasive 
fibrosis test that can be used sequentially and accurately reflect the progression 
or regression of fibrosis, and therefore be used a surrogate marker in clinical 
trials. It remains to be determined if MRE is such a test. 
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